Orange Book product · Brand (NDA)
UPTRAVI
SELEXIPAG
At a glance
Jul 29, 2021
Approved
Brand (NDA)
Application
Not listed
TE code
8
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jul 29, 2021
5 yr ago
Today
Patent 7205302 expires
Listed drug substance patent expiration.
Oct 31, 2026
in 4 mo
Patent 7205302*PED expires
Listed listed patent expiration.
Apr 30, 2027
in 11 mo
Patent 9173881 expires
Listed method-of-use patent (U-1798) expiration.
Aug 12, 2029
in 3 yr 2 mo
Patent 9173881*PED expires
Listed listed patent expiration.
Feb 12, 2030
in 3 yr 8 mo
Patent 9284280 expires
Listed method-of-use patent (U-1831) expiration.
Jun 25, 2030
in 4 yr 1 mo
Patent 8791122 expires
Listed drug substance patent expiration.
Aug 01, 2030
in 4 yr 2 mo
Patent 9284280*PED expires
Listed listed patent expiration.
Dec 25, 2030
in 4 yr 7 mo
Patent 8791122*PED expires
Listed listed patent expiration.
Feb 01, 2031
in 4 yr 8 mo
Pharmaceutical detail
Active ingredient
SELEXIPAG
Strength
1.8MG/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
TE code
Not listed
Application
NDA 214275
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (8)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7205302 | Oct 31, 2026 | in 4 mo | SubstanceProductU-1797 |
| 7205302*PED | Apr 30, 2027 | in 11 mo | |
| 9173881 | Aug 12, 2029 | in 3 yr 2 mo | U-1798 |
| 9173881*PED | Feb 12, 2030 | in 3 yr 8 mo | |
| 9284280 | Jun 25, 2030 | in 4 yr 1 mo | U-1831 |
| 8791122 | Aug 01, 2030 | in 4 yr 2 mo | SubstanceProduct |
| 9284280*PED | Dec 25, 2030 | in 4 yr 7 mo | |
| 8791122*PED | Feb 01, 2031 | in 4 yr 8 mo |
